Table 2.
Risk estimate in current concomitant use of CYP3A4 metabolized statins with clarithromycin within 30 days
| Risk of death or hospitalisation | RR (95 % CI) | P value |
|---|---|---|
| Unadjusted risk | 2.11 (1.79–2.48) | <0.001 |
| Adjusted for | ||
| Current agea | 1.18 (1.00–1.40) | 0.049 |
| Diabetes mellitus | 1.60 (1.34–1.91) | <0.001 |
| Cardiovascular disease | 1.33 (1.12–1.57) | 0.001 |
| Other antibiotics | 1.55 (1.28–1.87) | <0.001 |
| Multivariable adjusted for | ||
| age, diabetes mellitus, cardiovascular disease and other antibiotic therapy | 1.02 (0.85–1.22) | 0.85 |
Estimates come from a generalised linear model using a log link function; confidence intervals are based on robust standard errors
acurrent age as indicator variable of quintiles